D

Dynavax Technologies Corp
D

DVAX

11.330
USD
-0.15
(-1.26%)
مغلق
حجم التداول
88,949
الربح لكل سهم
0
العائد الربحي
-
P/E
57
حجم السوق
1,386,924,391
أصول ذات صلة
A
AEMD
0.00090
(0.24%)
0.37150 USD
B
BCRX
0.21000
(2.41%)
8.91000 USD
H
HRTX
-0.05000
(-2.14%)
2.29000 USD
L
LPCN
0.00000
(0.00%)
3.40000 USD
M
MNKD
0.05500
(1.11%)
4.99500 USD
P
PTN
-0.00340
(-1.55%)
0.21650 USD
S
SNDX
-0.100
(-0.72%)
13.700 USD
المزيد
الأخبار المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.